CR665

In today's world, CR665 is a topic of great relevance and interest to a wide spectrum of society. Both on a personal and professional level, CR665 arouses great curiosity and provokes continuous debates and reflections. From its origin to its impact today, CR665 has been evolving and acquiring new dimensions that invite further study and analysis. That is why in this article we propose to explore the different facets of CR665, analyzing its impact in different contexts, its influence on decision making and its relevance in the global sphere.

CR665
Names
IUPAC name
(R)-2-((R)-2-((R)-2-amino-3-phenylpropanamido)-3-phenylpropanamido)-N-((R)-5-guanidino-1-oxo-1-((pyridin-4-ylmethyl)amino)pentan-2-yl)hexanamide
Other names
CR 665; JNJ 38488502
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C36H49N9O4/c1-2-3-15-30(34(48)43-29(16-10-19-41-36(38)39)33(47)42-24-27-17-20-40-21-18-27)44-35(49)31(23-26-13-8-5-9-14-26)45-32(46)28(37)22-25-11-6-4-7-12-25/h4-9,11-14,17-18,20-21,28-31H,2-3,10,15-16,19,22-24,37H2,1H3,(H,42,47)(H,43,48)(H,44,49)(H,45,46)(H4,38,39,41)/t28-,29-,30-,31-/m1/s1
    Key: DBOGGOVKHSCMNB-OMRVPHBLSA-N
  • InChI=1/C36H49N9O4/c1-2-3-15-30(34(48)43-29(16-10-19-41-36(38)39)33(47)42-24-27-17-20-40-21-18-27)44-35(49)31(23-26-13-8-5-9-14-26)45-32(46)28(37)22-25-11-6-4-7-12-25/h4-9,11-14,17-18,20-21,28-31H,2-3,10,15-16,19,22-24,37H2,1H3,(H,42,47)(H,43,48)(H,44,49)(H,45,46)(H4,38,39,41)/t28-,29-,30-,31-/m1/s1
    Key: DBOGGOVKHSCMNB-OMRVPHBLBS
  • O=C(NCC1=CC=NC=C1)(NC((NC((CC2=CC=CC=C2)NC((CC3=CC=CC=C3)N)=O)=O)CCCC)=O)CCCNC(N)=N
Properties
C36H49N9O4
Molar mass 671.847 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).

CR665 (H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-Picolyl), also known by the previous developmental code names FE-200665 and JNJ-38488502, is an all D-amino acid peptide that acts as a peripherally restricted κ-opioid receptor agonist. The selectivity for FE 200665 is 1/16,900/84,600 for the human κ, μ, and δ opioid receptors, respectively. The dose of FE 200665 required to produce motor impairment (measure of CNS penetration) was 548 times higher than the dose required for antinociceptive activity.[1] It is being developed for use by Cara Therapeutics under the code name CR665.

A small, blinded study was done in healthy humans to determine the analgesic effects. CR665 was dosed at 0.36 mg/kg I.V., and was compared to 15 mg oxycodone orally. CR665 had analgesic effects on visceral pain, but produced a hyperalgesic response in a skin pinch test.[2]

See also

References

  1. ^ Vanderah, T. W.; Largent-Milnes, T.; Lai, J.; Porreca, F.; Houghten, R. A.; Menzaghi, F.; Wisniewski, K.; Stalewski, J.; Sueiras-Diaz, J.; Galyean, R.; Schteingart, C.; Junien, J. L.; Trojnar, J.; Rivière, P. J. (2008). "Novel D-Amino Acid Tetrapeptides Produce Potent Antinociception by Selectively Acting at Peripheral κ-Opioid Receptors". European Journal of Pharmacology. 583 (1): 62–72. doi:10.1016/j.ejphar.2008.01.011. PMID 18282565.
  2. ^ Arendt-Nielsen, L.; Olesen, A. E.; Staahl, C.; Menzaghi, F.; Kell, S.; Wong, G. Y.; Drewes, A. M. (2009). "Analgesic Efficacy of Peripheral κ-Opioid Receptor Agonist CR665 Compared to Oxycodone in a Multi-modal, Multi-Tissue Experimental Human Pain Model: Selective Effect on Visceral Pain". Anesthesiology. 111 (3): 616–624. doi:10.1097/ALN.0b013e3181af6356. PMID 19672186.


Stub icon

This analgesic-related article is a stub. You can help Wikipedia by expanding it.